Newsroom

[The Wall Street Journal] France Will use Taxes to Pressure Drug Makers on Hep C Prices

In an effort to blunt the high price of hepatitis C treatments, France plans to selectively tax drug makers when the total cost of their medicines exceeds […]

Read more

[Reuters] New cancer therapy comes of age, cost a ‘toxic’ side effect

A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects — but their high cost is a growing concern.

Read more

[The Washington Examiner] America’s other drug war

Winston Churchill famously described an appeaser as “one who feeds a crocodile, hoping it will eat him last.” Today, in a very different context, his remark captures the plight of the American pharmaceutical industry.

Read more

[The Washington Post] The new $84,000 hepatitis C treatment is losing momentum, for now

After recording the best launch of any drug in history, it looks like the pace is starting to slow down for Gilead Sciences’ Sovaldi — the new $84,000 hepatitis C cure that’s sparking a new focus on specialty drug costs.

Read more